Skin toxicity caused by EGFR antagonists-an autoinflammatory condition triggered by deregulated IL-1 signaling?

Journal of Cellular Physiology

Volumn 218, Issue 1, 2009, Pages 32-34

  Rodeck, Ulrich ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; AUTACOID; EGFR PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ACNE VULGARIS; DEREGULATION; FOLLICULITIS; HAIR FOLLICLE; HUMAN; INFLAMMATION; KERATINOCYTE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SKIN TOXICITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG ERUPTION; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; HAIR FOLLICLE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; KERATINOCYTES; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 58149150964     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21585     Document Type: Short Survey

References (30)

1. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J. 2002. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292-4302.
2. Bossi P, Liberatoscioli C, Bergamini C, Locati LD, Fava S, Rinaldi G, Orlandi E, Olmi P, Tagliabue E, Menard S, Licitra L. 2007. Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: Implications for the administration of EGFR inhibitors in previously irradiated patients. Ann Oncol 18:601-602.
3. Chen C-J, Kono H, Golenbock D, Reed G, Akira S, Rock KL. 2007. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. [see comment]. Nat Med 13:851-856.
4. Dierselhuis MP, Frenkel J, Wulffraat NM, Boelens JJ. 2005. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxford) 44:406-408.
5. Fleischmann RM, Iqbal I, Stern RL. 2004. Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opin Drug Saf 3:391 -403.
6. Groves RW, Sherman L, Mizutani H, Dower SK, Kupper TS. 1994. Detection of interleukin-1 receptors in human epidermis. Induction of the type II receptor after organ culture and in psoriasis. Am J Pathol 145:1048-1056.
7. Groves RW, Giri J, Sims J, Dower SK, Kupper TS. 1995. Inducible expression of type 2 IL-1 receptors by cultured human keratinocytes. Implications for IL-1-mediated processes in epidermis. J Immunol 154:4065-4072.
8. Hansen LA, Alexander N, Hogan ME, Sundberg JP, Dlugosz A, Threadgill DW, Magnuson T, Yuspa SH. 1997. Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. Am J Pathol 150:1959-1975.
9. Johansen C, Funding AT, Otkjaer K, Kragballe K, Jensen UB, Madsen M, Binderup L, Skak-NielsenT, Fjording MS, IversenL. 2006. Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol 176:1431-1438.
10. Kasper M, Schnidar H, Neill GW, Hanneder M, Klingler S, Blaas L, Schmid C, Hauser-Kronberger C, Regl G, Philpott MP, Aberger F. 2006. Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes. Mol Cell Biol 26:6283-6298.
11. Lacouture ME, Hwang C, Marymont MH, Patel J. 2007.Temporal dependence of the effect of radiation on erlotinib-induced skin rash. J Clin Oncol 25:2140 author reply 2141.
12. Lisby S, Hauser C. 2002. Transcriptional regulation of tumor necrosis factor-alpha in keratinocytes mediated by interleukin-I beta and tumor necrosis factor-alpha. Exp Dermatol 8:146-1452; 11: 592-598.
13. Louro ID, McKie-Bell P, Gosnell H, Brindley BC, Bucy RP, Ruppert JM. 1999. The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin. Cell Growth Differ 10:503-516.
14. Mascia F, Mariani V, Girolomoni G, Pastore S. 2003. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 163:303-312.
15. Mitra SS, Simcock R. 2006. Erlotinib induced skin rash spares skin in previous radiotherapy field. J Clin Oncol 24:e28-e29.
16. Pastore S, Mascia F, Mariotti F, Dattilo C, Mariani V, Girolomoni G. 2005. ERKl/2 regulates epidermal chemokine expression and skin inflammation. J Immunol 174:5047-5056.
17. Pastore S, Mascia F, Mariani V, Girolomoni G. 2008. The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol 123:788-790; 128: 1365-1374.
18. Perez-Soler R, Saltz L. 2005. Cutaneous adverse effects with HERl/EGFR-targetedagents:Is there a silver lining? J Clin Oncol 23:5235-5246.
19. Rauschmayr T, Groves RW, Kupper TS. l997. Keratinocyte expression of the type 2 interleukin I receptor mediates local and specific inhibition of interleukin l-mediated inflammation. Proc Natl Acad Sci USA 94:5814-5819.
20. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A, Armand J-P. 2004. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336-2347.
21. Robert C, Soria J-C, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand J-P, Le Chevalier T. 2005. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6:491-500.
22. Roberts RB, Arteaga CL, Threadgill DW. 2004. Modeling the cancer patient with genetically engineered mice: Prediction of toxicity from molecule-targeted therapies. Cancer Cell 5:115-120.
23. Rodeck U, Jost M, DuHadaway J, Kari C, Jensen PJ, Risse B, Ewert DL.1997.Regulation of Bcl-xL expression in human keratinocytes by cell-substratum adhesion and the epidermal growth factor receptor. Proc Natl Acad Sci USA 94:5067-5072.
24. Ruckert R, Lindner G, Bulfone-Paus S, Paus R. 2000. High-dose proinflammatory cytokines induce apoptosis of hair bulb keratinocytes in vivo. Br J Dermatol 143:1036-1039.
25. Shoham NG, Centola M, Mansfield E, Hull KM, Wood G, Wise CA, Kastner DL. 2003. Pyrin binds the PSTPIPI/CD2BPI protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci USA 100:13501-13506.
26. Sipples R. 2006. Common side effects of anti-EGFR therapy: Acneform rash. Semin Oncol Nurs 22:28-34.
27. Spiekstra SW, Toebak MJ, Sampat-Sardjoepersad S, van Beek PJ, Boorsma DM, Stoof TJ, von Blomberg BME, Scheper RJ, Bruynzeel DP, Rustemeyer T, Gibbs S. 2005. Induction of cytokine (interleukin-l alpha and tumor necrosis factor-alpha) and chemokine (CCL20, CCL27, and CXCL8) alarm signals after allergen and irritant exposure. Exp Dermatol 8:146-152; 14: 109-116.
28. Stichweh DS, Punaro M, Pascual V. 2005. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatr Dermatol 19:436-438; 22: 262-265.
29. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T, Herrup K, Harris RC, Barnard JA, Yuspa SH, Coffey RJ, Magnuson T.1995. Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science 307:1773-1776; 269:230-234.
30. Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes S, Lovett M. 2002. Mutations in CD2BPl disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 11:961-969.